Figure 1 Grip strength across the lifecourse

Slides:

Advertisements

Similar presentations

Figure 2 Electromechanical properties of OIHPs

Advertisements

Figure 6 Selected examples of TERS applications in material systems

Figure 2 Pathophysiology of hyperglycaemia in T2DM

Figure 4 Time course of the development of physiological changes

Figure 6 Effects of adiponectin on podocyte function

Figure 3 The adaptive and maladaptive energy matrices

Figure 3 Connexins in cartilage

Figure 5 Involvement of B cells in SLE

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Neuromuscular exercise

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Factors underlying metabolic alterations in osteoarthritis

Figure 1 Induction of immune tolerance

Figure 2 Risk factors for sarcopenia

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 2 Bad-metal behaviour and electron correlations

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 5 Defects in the JAK–STAT signalling pathway

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 1 Schematic comparison of expected

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Simplified EULAR and GRAPPA

Figure 3 Transcriptome studies performed in the target

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 3 Nucleic acid sensors in SLE

Figure 3 Defects in the T cell receptor signalling pathway

Figure 2 Cas9 targeting using crRNA (CRISPR

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Microbiota and osteoimmunology

Figure 3 Statistical approaches for the analysis of metabolomic data

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Figure 1 Cardiovascular risk and disease across the life-course

Figure 3 Cell-surface markers for NP cell differentiation

Figure 6 Lack of IRF5 causes a reduction in neutrophil influx

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Multi-hit model for autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Overview of biosimilar product development

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Treat to target, remission and low disease activity in SLE

Figure 1 Biospecimen handling pipeline

Figure 1 The current model of the pathogenesis of SLE

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 Metabolism of pterins

Figure 1 Principles for the diagnosis and management of osteoarthritis

Figure 1 Timing of the effects of deep brain stimulation

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Impaired mitochondrial capacity and function in heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Nuclear-penetrating autoantibodies and synthetic lethality

Figure 1 Overall worldwide prevalence ranges for SLE

Figure 2 Phenotypes of osteoarthritis

Figure 1 Differential effects of bone-forming agents on bone surfaces

Figure 4 4D printing schemes and time-evolving structure geometries

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 The main effects of adipokines on bone remodelling in osteoarthritis Figure 2 | The main effects of adipokines on bone remodelling in osteoarthritis.

Difference in the prevalence of sarcopenia and its components (low muscle strength and low muscle mass) between NDR, NPDR and PDR. NDR, no diabetic retinopathy;

Nat. Rev. Rheumatol. doi: /nrrheum

Mean decline in grip strength with aging is shown for participants categorized by baseline quartile of 2 h glucose (2HG). Mean decline in grip strength.

Presentation transcript:

Figure 1 Grip strength across the lifecourse Figure 1 | Grip strength across the lifecourse. Factors that affect muscle can do so from an early age by influencing the development of peak muscle mass and/or rates of muscle loss. Peak muscle mass is attained in youth and followed by decline in grip strength in later life. Grip strength over the course of life is illustrated here. This figure has been adapted from the pattern of grip strength observed by Dodds et al.12, which is published under an open-access licence https://creativecommons.org/licenses/by/4.0/ This figure has been adapted from Dodds et al.12, which is published under an open-access licence https://creativecommons. org/licenses/by/4.0/ Dennison, E. M. et al. (2017) Epidemiology of sarcopenia and insight into possible therapeutic targets Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.60